Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
In β-thalassemia and polycythemia vera (PV), disordered erythropoiesis triggers severe pathophysiological manifestations. β-Thalassemia is characterized by ineffective erythropoiesis, reduced production of erythrocytes, anemia, and iron overload and PV by erythrocytosis and thrombosis. Minihepcidins are hepcidin agonists that have been previously shown to prevent iron overload in murine models of hemochromatosis and induce iron-restricted erythropoiesis at higher doses. Here, we show that in young Hbb(th3/+) mice, which serve as a model of untransfused β-thalassemia, minihepcidin ameliorates ineffective erythropoiesis, anemia, and iron overload. In older mice with untransfused β-thalassemia, minihepcidin improves erythropoiesis and does not alter the beneficial effect of the iron chelator deferiprone on iron overload. In PV mice that express the orthologous JAK2 mutation causing human PV, administration of minihepcidin significantly reduces splenomegaly and normalizes hematocrit levels. These studies indicate that drug-like minihepcidins have a potential as future therapeutics for untransfused β-thalassemia and PV.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mini-hepcidin pro-drug M009 is metabolized to active mini-hepcidin M004 and was recently shown to improve erythropoiesis in Hbbth3∕+ mice and in a mouse model of polycythemia vera (Casu et al., 2016).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Casu et al., 2016
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Identification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208500 · Cited by 846
Ineffective erythropoiesis in Stat5a−/−5b−/− mice due to decreased survival of early erythroblasts
Socolovsky, M., Nam, H.-S., Fleming, M. D., Haase, V. H., Brugnara, C., & Lodish, H. F. (2001) · Blood · doi:10.1182/blood.v98.12.3261 · Cited by 681 · cited 1×
“Overexpression of EPO leads to increased phosphorylation of the Jak2 kinase and overexpression of the genes downstreamof the Jak2-Stat5 pathway involved in cell proliferation and survival.(20,24,25) As minihepcidin improved erythropoiesis and ameliorated anemia, EPO concentrations declined (Figure 4J).”
BackgroundMullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.015 · Cited by 395 · cited 2×
“Jak2 VAV-Cre double-transgenic mice developed a PV-like phenotype, which was transplantable, as previously demonstrated.(11) To determine if treatment with minihepcidin could improve hypoxia in our mousemodel of b-thalassemia, the hypoxia reporter mouse, oxygen-dependent degradation luciferase (ODD-Luc), was crossedwi…”
MethodLiver iron concentrations and urinary hepcidin in -thalassemia
Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., & Nemeth, E. (2007) · Haematologica · doi:10.3324/haematol.10842 · Cited by 365 · cited 2×
“In b-thalassemia and anemia, increased EPO levels and expanded but ineffective erythropoiesis result in lowered hepcidin levels, increased intestinal iron absorption, and TSAT.3,6,8,21,27 In turn, excess iron contributes to the development and worsening of ineffective erythropoiesis and reduced erythroblast maturation…”
Self-citationNon-transfusion-dependent thalassemias
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013) · Haematologica · doi:10.3324/haematol.2012.066845 · Cited by 326
Cited by
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319
Self-citationIron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Iron in infection and immunity
Nairz, M., & Weiss, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100864 · Cited by 359
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Self-citation
Metadata
- Authors
- Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., Ganz, T., MacDonald, B., & Rivella, S.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Erythropoiesis Laboratory, and
- New York Blood Center (US)
- Department of Pediatrics, and
- Saint Louis University (US)
- University of Michigan (US)
- Department of Medicine, and
- University of California, Los Angeles (US)
- Merganser Biotech Inc., King of Prussia, PA;
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-07-14
- Volume
- 128
- Issue
- 2
- Pages
- 265-276
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4946204
- OpenAlex
- W2401643476
- Cited by
- 148
- References
- 28
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 23 · 2020: 19 · 2019: 18 · 2018: 17 · 2017: 17 · 2016: 2
- FWCI
- 17.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K08HL105682)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK090554, R01DK107309, R01DK095201, R01DK095112, R01DK107670)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Keywords
- beta-thalassemia, polycythemia vera, iron overload, ineffective erythropoiesis, anemia, deferiprone, JAK2 mutation, splenomegaly, disease modifiers, iron chelation
- MeSH terms
- Animals, Erythropoiesis, Mice, Mutant Strains, Peptides, Polycythemia Vera, beta-Thalassemia, Amino Acid Substitution, Mutation, Missense, Mice, Janus Kinase 2, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. https://app.cochat.ai/papers/10.1182/blood-2015-10-676742
- The paper
- Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., Ganz, T., MacDonald, B., & Rivella, S. (2016). Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. Blood. https://doi.org/10.1182/blood-2015-10-676742
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.